The Macrolide Antibiotics Market is anticipated to reach USD 146,432.1 Million by 2030 at 13.1% CAGR during the forecast period 2022-2030. Macrolides are a class of antibiotics derived from Saccharopolyspora erythraea. They inhibit protein synthesis in bacteria by binding to the 50S ribosomal element and effective against gram positive bacteria and intracellular pathogens such as Legionella, Mycoplasma, and Chlamydia. It primarily act as a bacteriostatic agent against many strains of Corynebacteria, Listeria, Moxicella, Streptococci, Neisseria meningitides, Staphylococci, Clostridia, and Haemophilus sp.
The macrolide antibiotics market exhibits a significant growth across the globe owing to the increasing prevalence of skin infections and growing demand for drugs against bacterial skin infections.
Major concerns involved in the use of macrolide antibiotics are GI disturbances and inhibition of hepatic metabolism. According to a study published in the Journal of the American College of Cardiology, macrolide antibiotics may increase the risk of sudden cardiac death, ventricular tachyarrhythmias, and cardiovascular death in patients, which may hinder the growth of the macrolide antibiotics market over the review period.
FIGURE 1 Global Macrolide Antibiotics Market, By Region, 2016 (%) Key Players in the Macrolide antibiotics Market
Segments The macrolide antibiotics market is segmented on the basis of drugs which includes azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin.
On the basis of route of administration, the macrolide antibiotics market is segmented into oral and parenteral.
On the basis of indication, the macrolide antibiotics market is segmented into infection due to mycoplasma pneumoniae, legionella sp, or bordetella pertussis, symptomatic cat-scratch disease, bacillary angiomatosis, peliosis hepatis in patients with AIDS, cerebral toxoplasmosis, uncomplicated skin infections, and others.
On the basis of end user, the macrolide antibiotics market is segmented into hospitals, dermatology clinics, pharmaceutical companies, and others.
Regional Analysis of the Macrolide Antibiotics Market The American region accounted for the largest share of the macrolide antibiotics market due to increasing prevalence of skin infections, and presence of prominent market players. The prevalence of bacterial skin infection increasing in the US from the last few years. Also, the number of visits to the emergency department has increased. Furthermore, increasing dose of antibiotics in number of out-patient settings in the U.S, which will drive the growth of the macrolide antibiotics market over the forecast period.
Europe is the second largest market that holds a noticeable share of the macrolide antibiotics market. In France, prevalence of symptomatic cat-scratch disease has been increasing from the last few years.
In Asia Pacific, prevalence of skin disease is found to be increasing in Japan. Rising prevalence of skin diseases, and growing awareness about the use of macrolides for the treatment of uncomplicated skin infections drives the macrolide antibiotics market in Asia Pacific.
The Middle East and Africa show steady growth in the macrolide antibiotics market.Intended Audience
|Market Size||USD 146,432.1 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drugs, Route of administration, Indication, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.),and WOCKHARDT (U.S.)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||